Abstract
In type 2 diabetes, several lesions have been identified and drugs are being developed that target these lesions. This review considers agents that have been introduced to Europe since 2006, particularly the glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 inhibitors (gliptins) that represent new classes of agent, both of which target the enteroinsular axis. The GLP-1 analogues and gliptins reduce hyperglycaemia without promoting weight gain, with the former being associated with weight loss. Agents advanced in development, new fixed-dose combination tablets and new formulations of established agents are also considered.
| Original language | English |
|---|---|
| Pages (from-to) | 85-87 |
| Number of pages | 3 |
| Journal | European Diabetes Nursing |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Sept 2009 |
Keywords
- DPP-4 inhibitors
- gliptins
- GLP-1 analogues
- SGLT-2 inhibitors
- type 2 diabetes